Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Patient (pt) characteristics, treatment patterns, and outcomes in unresectable hepatocellular carcinoma (uHCC) treated with first-line (1L) systemic therapy in the United States (US). Patterns of ...

The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.

The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCCAmezalpat builds momentum with both ...

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

Hundreds of a people who have chronic liver disease are being helped by an NHS trust's service that helps them attend vital ...

Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response rates and improved survival for patients with unresectable hepatocellular ...